Menu
Search
|

Menu

Close
X

Enanta Pharmaceuticals Inc ENTA.OQ (NASDAQ Stock Exchange Global Select Market)

78.94 USD
-1.13 (-1.41%)
As of Nov 21
chart
Previous Close 80.07
Open 80.98
Volume 66,031
3m Avg Volume 96,256
Today’s High 80.98
Today’s Low 77.74
52 Week High 127.74
52 Week Low 44.54
Shares Outstanding (mil) 19.09
Market Capitalization (mil) 927.79
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
139
FY17
103
FY16
88
FY15
161
EPS (USD)
FY18
2.353
FY17
0.798
FY16
1.121
FY15
4.097
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.60
Price to Sales (TTM)
vs sector
23.35
5.69
Price to Book (MRQ)
vs sector
3.56
5.11
Price to Cash Flow (TTM)
vs sector
--
23.53
Total Debt to Equity (MRQ)
vs sector
0.25
15.71
LT Debt to Equity (MRQ)
vs sector
0.22
11.53
Return on Investment (TTM)
vs sector
-7.67
15.05
Return on Equity (TTM)
vs sector
-7.78
16.62

EXECUTIVE LEADERSHIP

Bruce Carter
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Jay Luly
President, Chief Executive Officer, Director, Since 2003
Salary: $581,203.00
Bonus: --
Paul Mellett
Chief Financial Officer, Senior Vice President - Finance & Administration, Since 2003
Salary: $359,930.00
Bonus: $93,893.00
Yat Sun Or
Senior Vice President - Research & Development, Chief Scientific Officer, Since 1999
Salary: $400,975.00
Bonus: $121,255.00
Nathaniel Gardiner
Senior Vice President, General Counsel, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

500 Arsenal St
WATERTOWN   MA   02472-2806

Phone: +1617.6070800

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.

SPONSORED STORIES